The Interleukin-17A inhibitor ixekzumab  led to high clinical response rates and sustained efficacy in a majority of patients with moderate to severe plaque psoriasis, data show. The 60-week follow-up data showed that 54% of patients treated with either of two doses of ixekizumab remained clear of lesions one year after treatment. In a separate study, long-term follow-up from a randomized trial showed sustained superiority for the biologic secukinumab over ustekinumab in patients with moderate to severe plaque psoriasis.

Click here for more.